Median Technologies · EURONEXT:ALMDT
Median Technologies — Investor Presentation (September 2026)
27 slides from Median Technologies's investor presentation, September 2026
Slide 1: AI-Powered Imaging: New Horizons in Fighting Cancer
AI-Powered Imaging: New Horizons in Fighting Cancer Investor Presentation September-October 2026 MEDIAN TECHNOLOGIES
Slide 2: Important Notice
IMPORTANT NOTICE – YOU MUST READ THE FOLLOWING BEFORE CONTINUING This presentation contains forward-looking statements within the meaning of applicable securities laws. We may also make written or oral forward-looking statements in our publicly available financial information, press releases and oth
Slide 3: Providing invaluable clinical insights where others only see images
Providing invaluable clinical insights where others only Providing Adding ProvidingseeInvaluable images Clinical More Accurate More Value AI-Driven to Oncology Insights Where Others Diagnosis Clinical Trials Only See Images Leveraging Proprietary AI, Generating More Computer Vision, and Signal AI-Dr
Slide 4: Median Participates on both Sides of the Cancer Equation
Median Participates on both Sides of the Cancer Equation: Finding Disease Earlier and Helping Develop Better Treatments One mission. Two businesses Median owns two distinct oncology businesses with meaningful value-creation potential. FIND CANCER EARLIER DEVELOP CANCER TREATMENTS BETTER AI-powered c
Slide 5: Proven and Experienced Management and Board of Directors
Proven and Experienced Management and Board of Directors MANAGEMENT Fredrik Brag Oran Muduroglu Jean-Christophe Montigny Thomas Bonnefont Nicolas Dano Chrystel Brun Chief Executive Officer, Executive Chairman of the Board, Chief Financial Officer Chief Operating Officer & Chief Operating Officer & C
Slide 6: Strong Momentum from Recent Business Catalysts
Strong Momentum from Recent Business Catalysts • Achieved FDA 510(k) clearance for eyonis® LCS • Signed strategic distribution agreement with Tempus for eyonis® LCS • Named Oran Muduroglu as President of Median eyonis Inc. to lead the eyonis® LCS U.S. launch and scale-up High Commercial • Achieved e
Slide 7: Successful Oversubscribed €50 million Capital Increase
Successful Oversubscribed €50 million Capital Increase Results announced on June 3rd, 2026 Current cash runway extends through • Institutional and retail investors • Heavily oversubscribe demonstrating HY 2028 very strong market support Potential upside to cash position from • Capital increase combi
Slide 8: Median's Shareholding Structure Post Capital Increase
Median’s Shareholding Structure Post Capital Increase 10.64% Outstanding shares 24.60% as of June 26, 2026: 8.81% 49,010,638 5.21% 3.09% 3.08% 3.07% 41.50% Anne Helen and Fredrik Lungstrom Katarina Martinson AB Celestial Successor Fund LP Venture S.a.r.l Furui Medical Science Company Lion Point LP F
Slide 9: AI imaging is revolutionizing cancer care
AI imaging is revolutionizing cancer care 9 mediantechnologies.com | Corporate Update | September - October 2026
Slide 10: The Future of Cancer is Before Symptoms
The Future of Cancer is Before Symptoms Our ambition is to build the world's leading AI-powered cancer diagnosis company—finding multiple cancers at the stage when they can still be cured Earlier Detection. Brighter Tomorrows. 10 mediantechnologies.com | Corporate Update | September - October 2026
Slide 11: Lung Is the Beachhead. Pan-cancer Is the Ambition
Lung Is the Beachhead. Pan-cancer Is the Ambition Lung cancer proves what is possible. The same regulated AI platform is designed to expand across organs and cancer indications INCIDENTAL In LUNG PULMONARY progress 18.7% of deaths NODULES LIVER / HCC In COLORECTAL Future 7.8% of deaths progress 9.3%
Slide 12: Why Target Lung Cancer as eyonis Beachhead Market?
Why Target Lung Cancer as eyonis® Beachhead Market? Stage at diagnosis changes everything Latest I-ELCAP 20-year Outcomes (3) Most lung cancers are More than 80% diagnosed at an of screen-detected lung advanced stage when cancers were diagnosed as #1 treatment options are Stage I Cancer Killer more
Slide 13: Lung Cancer Alone Opens a ~$10B U.S. Market
Lung Cancer Alone Opens a ~$10B U.S. Market 14.5m soon 19m ~$650 ~$9.4B and 27m × ≈ Screening-eligible Americans Current reimbursement Annual theoretical procedure pathway value 13 mediantechnologies.com | Corporate Update | September - October 2026
Slide 14: The only FDA Approved, CE Marked AI-based SaMD for LCS
The only FDA Approved, CE Marked AI-based SaMD for LCS Clinical FDA 510(k) Commercial Validation CE Mark Deployment ✓ ✓ DETECTION-ONLY TOOLS WITH is the first and only FDA-cleared and CE marked AI Software as a Medical Device combining Multiple indeterminate nodules leading to additional AI identifi
Slide 15: Seamlessly Enabling Scale-Up of Lung Cancer Screening Workflow
Seamlessly Enabling Scale-Up of Lung Cancer Screening Workflow • Easy-to-use • Optimizes radiologist's time • Increases workflow standardization • Compatible with any CT-scan and any PACS system • No manual intervention • Greater accuracy & efficiency 15 mediantechnologies.com | Corporate Update | S
Slide 16: Clinical Impact in Lung Cancer Screening
Clinical Impact in Lung Cancer Screening More accurate diagnosis. A clearer path for patients. Screen-detected Lung Cancer DETECTION-ONLY TOOLS WITH 93.3% 92.4% 99.9% SENSITIVITY* SPECIFICITY* NPV* • Higher Detection - Find more cancers • Fewer False Positives - Reduce unnecessary escalation • Bette
Slide 17: eyonis LCS Commercial Launch and Scale-Up in the U.S.
eyonis® LCS Commercial Launch and Scale-Up in the U.S. Key Pillars of the U.S. Commercial Strategy Build-out of direct enterprise eyonis® LCS Strategic distribution sales organization sales execution agreements • Expansion of robust U.S.-based • Detailed customer and payor • Tempus partnership annou
Slide 18: Three Paths to Market Distribution
Three Paths to Market Distribution One diagnostic intelligence layer, integrated where imaging teams already work, insuring all roads lead to eyonis® LCS Inside Detection Algorithms 01 Embed Eyonis diagnostic intelligence inside lesion- detection products. At PACS Reading Stations 4,000 02 Place dia
Slide 19: Existing Reimbursement Pathway to Support U.S. Launch
Existing Reimbursement Pathway to Support U.S. Launch Total Medicare Hospital Payment is • Established Category III CPT codes (0721T & LDCT $107 + eyonis® LCS $650 0722T) for CT-based tissue characterization Existing Hospital • CMS reimbursement pathway in place, with CPT Code CPT Description LDCT O
Slide 20: European Go-to-Market (1/2)
European Go-to-Market (1/2) Strategy centered on lung cancer national programs HANSE + study German LCS officially started 1st April ‘26 Successful Polish pilot Polish LCS 1st October ‘26 Successful pilot in England Potential extension to UK RISP national pilot Potential implementation Discussion on
Slide 21: European Go-to-Market (2/2)
European Go-to-Market (2/2) 1 Small dedicated team 2 Centered on TOP 6 countries by LCS programs time order 3 Heavily engage KOLs (France, Germany, Italy and UK) 4 Work-out market access, pricing & reimbursement 5 Exploit faster temporary reimbursement scheme (forfait innovation) 6 Plan for 2 to 3 H
Slide 22: Clear Growth Strategy Designed to Expand eyonis' Reach
Clear Growth Strategy Designed to Expand eyonis’ Reach 1 2 3 Generate Sales in Drive Traction Expand Portfolio the U.S. In Europe 22 mediantechnologies.com | Corporate Update | September - October 2026
Slide 23: iCRO
iCRO AI-powered imaging to revolutionize drug development 23 mediantechnologies.com | Corporate Update | September - October 2026
Slide 24: iCRO: the Second Value Engine at the Intersection of Oncology, Imaging, Data and AI
iCRO: the Second Value Engine at the Intersection of Oncology, Imaging, Data and AI While eyonis® transforms how cancer is diagnosed, iCRO helps transform how cancer therapies are developed. RECORD BACKLOG €82.4M As of June 30, 2026 (unaudited) iCRO empowers biopharma sponsors Select better patients
Slide 25: Strong Traction with Leading Biopharma
Strong Traction with Leading Biopharma Global Footprint: 95+ 7K+ Evolution of Oncology Studies Managed by Median vs Phases Across U.S., Europe, Biopharmaceutical Site Network 400 and Asia Clients 363 347 350 306 11 300 286 Preferred Imaging 49 274 FDA-approved 249 Services Provider Studies, no findi
Slide 26: Well-Defined iCRO Growth Acceleration Strategy
Well-Defined iCRO Growth Acceleration Strategy Targets for Leveraging the Transformative Power of Imaging AI for Drug Development 1 2 3 Collaborations Geographical Operational Focus Strategy Establish AI imaging drug EU/U.S.: be selected as Further profitability development preferred provider by big
Slide 27: Our Core Values
Our Core Values Leading innovation with purpose Combine the spirit of innovation with our passion and conviction to help cure cancer and other debilitating diseases. Committing to quality in all we do Be dedicated to quality in everything we do. Quality begins with us and we are committed to it. Sup
Median Technologies — Investor Presentation (September 2026) on 6ix